Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical leader pioneering treatments for central nervous system disorders, including depression and rare neurological conditions. This page provides investors and researchers with a comprehensive repository of official company updates and third-party analysis.
Access timely announcements on clinical trial milestones, regulatory developments, and strategic collaborations shaping the future of neuroscience therapeutics. Our curated feed includes earnings reports, research publications, and partnership disclosures critical for evaluating SAGE’s progress in addressing unmet medical needs.
Key content focuses on GABA/NMDA receptor-targeted therapies, pipeline advancements for postpartum depression treatments, and epilepsy-related innovations. Bookmark this page to monitor how Sage Therapeutics’ scientific expertise translates into potential market opportunities within the competitive CNS pharmaceutical landscape.
Sage Therapeutics will host a live webcast on May 2, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and recent business updates. This event will be accessible via the Investor page on Sage’s website. A replay of the webcast will be available for 30 days post-event.
Sage Therapeutics focuses on advancing brain health solutions, committed to developing life-changing medicines for brain health. More information about their mission can be found on their website.
Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company focused on brain health, announced its participation in the Stifel 2023 CNS Days on March 29, 2023, at 11:00 a.m. ET. The presentation will be available via live webcast on Sage's investor page. A replay will be accessible for 30 days following the event. Sage's mission is to develop transformative therapies for brain health, aiming to empower individuals to thrive. For more details, visit www.sagerx.com.
Sage Therapeutics, Inc. (NASDAQ: SAGE) has appointed Jessica Federer to its Board of Directors. With a strong background in digital health and innovation, Federer aims to enhance the company's growth in maternal mental health care. She previously served as the first Chief Digital Officer for Bayer AG, where she shaped global digital strategy. Federer expressed her commitment to redefining brain health treatment, highlighting the potential of data strategies in this area. CEO Barry Greene noted her patient-first approach aligns with Sage's core values and ambitions. This strategic appointment could drive future growth for the company.
Sage Therapeutics (SAGE) and Biogen (BIIB) announced that the FDA will not convene an advisory committee to discuss the New Drug Application for zuranolone, a treatment for major depressive disorder (MDD) and postpartum depression (PPD). This investigational drug has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) action date set for August 5, 2023. Zuranolone is part of clinical programs LANDSCAPE and NEST, which include several studies across thousands of participants. The companies remain optimistic about zuranolone's potential, but there are inherent risks and uncertainties in drug approval processes.
Sage Therapeutics (NASDAQ: SAGE) will present at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 10:30 a.m. ET in Boston, MA. Investors can access the live webcast on Sage's investor page, with a replay available for 30 days after the event. Sage Therapeutics focuses on pioneering brain health solutions aimed at delivering transformative medicines, enhancing the quality of life for individuals. For further details, visit www.sagerx.com.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
